Scheen, A. J. & Van Gaal, L. F. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2, 911-922 (2014).
Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27-36 (2015).
Sadry, S. A. & Drucker, D. J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9, 425-433 (2013).
Neumiller, J. J. Incretin-based therapies. Med. Clin. North Am. 99, 107-129 (2015).
Campbell, J. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819-837 (2013).
Unger, R. H. & Cherrington, A. D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122, 4-12 (2012).
Lund, A., Bagger, J. I., Christensen, M., Knop, F. K. & Vilsbøll, T. Glucagon and type 2 diabetes: the return of the α cell. Curr. Diab. Rep. 14, 555 (2014).
Arafat, A. M. et al. Glucagon regulates orexin A secretion in humans and rodents. Diabetologia 57, 2108-2116 (2014).
Tan, T. M. et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62, 1131-1138 (2013).
Cegla, J. et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63, 3711-3720 (2014).
